🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 18 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
03/09/2009 11,28 11,28 10,32 10,74 +0,56% 8,51% 589.350
02/09/2009 11,64 11,76 10,38 10,68 -14,42% 11,86% 1.353.300
01/09/2009 10,80 13,14 10,56 12,48 +21,64% 23,89% 4.726.167
31/08/2009 8,70 10,50 8,64 10,26 +17,93% 21,38% 2.540.700
28/08/2009 8,88 8,88 8,58 8,70 -1,36% 3,38% 455.750
27/08/2009 8,64 8,94 8,28 8,82 +3,52% 7,64% 708.517
26/08/2009 8,94 9,18 8,46 8,52 +2,16% 8,05% 1.895.950
25/08/2009 8,22 8,46 8,04 8,34 +2,96% 5,11% 745.833
24/08/2009 8,52 8,64 7,92 8,10 -2,88% 8,45% 869.500
21/08/2009 8,34 8,46 7,86 8,34 +3,73% 7,19% 1.295.750
20/08/2009 8,10 8,28 7,86 8,04 -24,72% 5,19% 3.520.767
19/08/2009 10,20 11,28 10,08 10,68 +2,89% 11,76% 235.350
18/08/2009 10,02 10,98 9,96 10,38 +2,37% 10,18% 151.583
17/08/2009 10,26 10,50 9,96 10,14 -5,06% 5,26% 222.800
14/08/2009 11,16 11,58 10,62 10,68 -6,32% 8,60% 273.917
13/08/2009 12,42 12,48 11,16 11,40 -8,65% 10,63% 293.983
12/08/2009 12,42 13,20 12,36 12,48 -1,42% 6,76% 173.200
11/08/2009 12,96 13,08 12,36 12,66 -4,09% 5,56% 182.400
10/08/2009 13,80 14,10 12,90 13,20 -8,33% 8,70% 220.750
07/08/2009 13,50 14,76 13,20 14,40 +9,09% 11,56% 292.250
06/08/2009 14,10 14,40 12,96 13,20 -6,38% 10,21% 168.683
05/08/2009 13,44 14,40 12,90 14,10 +5,38% 11,16% 226.350
04/08/2009 12,60 13,74 12,00 13,38 +4,21% 13,81% 243.733
03/08/2009 14,40 14,58 12,72 12,84 -6,96% 12,92% 244.783
31/07/2009 13,98 14,88 13,26 13,80 -2,95% 11,59% 236.467
30/07/2009 15,90 16,38 13,86 14,22 +3,49% 15,85% 564.117
29/07/2009 14,46 15,84 13,68 13,74 -7,29% 14,94% 676.983
28/07/2009 14,82 16,08 13,86 14,82 +17,62% 14,98% 1.234.867
27/07/2009 11,64 13,56 11,28 12,60 +9,95% 19,59% 418.467
24/07/2009 10,26 12,06 10,26 11,46 +9,14% 17,54% 433.500